The challenges of quantitative measurement of lung deposition using 99mTc-DTPA from delivery systems with very different delivery times

Journal of Aerosol Medicine: Deposition, Clearance, and Effects in the Lung

Volumn 20, Issue 3, 2007, Pages 320-330

  Coates, Allan L ^a   Green, Maria ^a   Leung, Kitty ^a   Louca, Emily ^a   Tservistas, Markus ^b   Chan, Jeffrey ^a   Ribeiro, Nancy ^a   Charron, Martin ^a  

^a HOSPITAL FOR SICK CHILDREN   (Canada)

^b PARI GmbH   (Germany)

Author keywords

99mTc DTPA; Cystic fibrosis; Inhaled antibiotics; Nebulization; Tobramycin

Indexed keywords

ANTIBIOTIC AGENT; COBALT 57; PENTETATE TECHNETIUM TC 99M; TOBRAMYCIN; TOBRAMYCIN SULFATE;

ACCURACY; ADULT; AEROSOL; ARTICLE; CYSTIC FIBROSIS; DEVICE; DRUG DELIVERY SYSTEM; HUMAN; HUMAN EXPERIMENT; IMAGE ANALYSIS; ISOTOPE LABELING; LUNG; LUNG CIRCULATION; MALE; MATHEMATICAL ANALYSIS; MEASUREMENT; MUCOCILIARY CLEARANCE; NEBULIZATION; NEBULIZER; NORMAL HUMAN; QUALITY CONTROL; QUANTITATIVE ANALYSIS; RADIOACTIVITY; TECHNIQUE; VIBRATION;

ADMINISTRATION, INHALATION; ADULT; AEROSOLS; ANTI-BACTERIAL AGENTS; DRUG DELIVERY SYSTEMS; EQUIPMENT DESIGN; HUMANS; IMAGE INTERPRETATION, COMPUTER-ASSISTED; LUNG; MALE; NEBULIZERS AND VAPORIZERS; RADIOPHARMACEUTICALS; TECHNETIUM TC 99M PENTETATE; TECHNOLOGY, PHARMACEUTICAL; TIME FACTORS; TOBRAMYCIN; VIBRATION;

EID: 34648830387     PISSN: 08942684     EISSN: None     Source Type: Journal    
DOI: 10.1089/jam.2007.0620     Document Type: Article

References (30)

1. Iacono, A.T., B.A. Johnson, W.F. Grgurich, J.G. Youssef, T.E. Corcoran, D.A. Seiler, J.H. Dauber, G.C. Smaldone, A. Zeevi, S.A. Youssem, J.J. Fung, G.J. Burckart, K.R. McCurry, and B.P. Griffith. 2006. A randomized trial of inhaled cyclosporine in lung-transplant recipients. N. Engl. J. Med. 354:141-150.
2. Morton-Eggleston, E., and E.J. Barrett. 2006. Inhaled insulin. BMJ 6:1043-1044.
3. Ramsey, B.W., J. Burns, and A.L. Smith. 1997. Safety and efficacy of tobramycin solution for inhalation in patients with cystic fibrosis: the results of two Phase III placebo controlled clinical trials. Pediatr. Pulmonol. 14:S137-S138.
4. MacLusky, I.B., R. Gold, M.L. Corey, and H. Levison. 1989. Long-term effects of inhaled tobramycin in patients with cystic fibrosis colonized with Pseudomonas aeruginosa. Pediatr. Pulmonol. 7:42-48.
5. Gibson, R.L., J. Emerson, S. McNamara, J.L. Burns, M. Rosenfeld, A. Yunker, N. Hamblett, F. Accurso, M. Dovey, P.W. Hiatt, M.W. Konstan, R. Moss, G. Retsch-Bogart, J. Wagener, D. Waltz, R. Wilmott, P.L. Zeitlin, B. Ramsey, and the Cystic Fibrosis Therapeutics De-velopment Network Study Group. 2003. Significant microbiological effect of inhaled tobramycin in young children with cystic fibrosis. Am. J. Respir. Crit. Care Med. 167:841-849.
6. Hodson, M.E., C.G. Gallagher, and J.R.W. Govan. 2003. A randomized clinical trial of nebulised tobramycin or Colistin in cystic fibrosis. Eur. Respir. J. 20:658-664.
7. Lay, J.C., M.R. Stang, P.E. Fisher, J.R. Yankaskas, and W.D. Bennett. 2003. Airway retention of materials of different solubility following local intrabronchial deposition in dogs. J. Aerosol Med. 16:153-166.
8. 99mTc labelled colloids to glass vials. Nucl. Med. Commun. 11:375-381.
9. Porter, W.C., H.J. Dworkin, and R.F. Gutkowski. 1975. Vial retention of technetium-99m sulphur colloid in commercial kits. Am. J. Hosp. Pharm. 1141-1143.
10. Coates, G., and H.M. O'Brodovich. 1986. Measurement of pulmonary epithelial permeability with 99mTc-DTPA aerosol. Semin. Nuclear Med. XVI:275-284.
11. O'Brodovich, H.M., G. Coates, J. Kay, and D. Muysson. 1989. Simultaneous measurement of lung clearance rates for Tc- and In-DTPA in normal and damaged lungs. J. Appl. Physiol. 66:2293-2297.
12. Regnis, J.A., M. Robinson, D.L. Bailey, P. Cook, P. Hooper, H.K. Chan, I. Gonda, and P.T.P. Bye. 1994. Mucociliary clearance in patients with cystic fibrosis and in normal subjects. Am. J. Respir. Crit. Care Med. 150:66-71.
13. Robinson, M., S. Eberl, C. Tomlinson, E. Daviskas, J.A. Regnis, D.L. Bailey, P.J. Torzillo, M. Menache, and P.T.P. Bye. 2000. Regional mucociliary clearance in patients with cystic fibrosis. J. Aerosol Med. 13:73-86.
14. Sorenson, J.A., and D.L. Phelps. 1980. Problems in radioactive detection and measurement. In Physics in Nuclear Medicine. Grune and Gratton Inc, New York, 208-228.
15. Macey, D.J., and R. Marshall. 1982. Absolute quantitation of radiotracer uptake in the lungs using a gamma camera. J. Nucl. Med. 23:731-735.
16. Pitcairn, G.R., and S.P. Newman. 1997. Tissue attenuation corrections in gamma scintigraphy. J. Aerosol Med. 10:187-198.
17. Forge, N.I., P.J. Mountford, and M.J. O'Doherty. 1993. Quantification of technetium-99m lung radioactivity from planar images. Eur. J. Nucl. Med. 20:10-15.
18. Coates, A.L., C.F. MacNeish, L. Dinh, T. Rollin, S. Gagnon, S.L. Ho, and L.C. Lands. 2000. Accounting for radioactivity before and after nebulization of tobramycin to insure accuracy of quantification of lung deposition. J. Aerosol Med. 13:169-178.
19. Ramsey, B.W., M.S. Pepe, J.F. Quan, K.L. Otto, A.B. Montgomery, J. Williams-Warren, K.M. Vasiljev, D.S. Borowitz, C.M. Bowman, B.C. Marshall, S. Marshall, and A.L. Smith. 1999. Intermittent administration of inhaled tobramycin in patients with cystic fibrosis. N. Engl. J. Med. 340:23-30.
20. Leung, K., E. Louca, and A.L. Coates. 2004. Comparison of breath enhanced to breath actuated nebulizers for rate, consistency and efficiency. Chest 26:1619-1627.
21. Barends, D.M., Zwaan C.L., and A. Hulshoff. 1981. Microdetermination of tobramycin in serum by high-performance liquid chromatography with ultraviolet detection. J. Chromatogr. 225:417-426.
22. Manis, L.E., and M.J. Wilcox. 2000. Reversed-Phase HPLC Analysis of Aminoglycoside Antibiotics: Using Evaporative Light Scattering Detection. Alltech Associates, Deerfield, IL.
23. Marple, V.A., D.L. Roberts, F.J. Romay, N.C. Miller, K.G. Truman, M.J. Holroyd, J.P. Mitchell, and D. Hochrainer. 2003. Next generation pharmaceutical impactor (A new impactor for pharmaceutical inhaler testing)/ Part 1. Design. J. Aerosol. Med. 16:283-299.
24. Mitchell, J.P. 2000. The next generation impactor (NGI): results from the evaluation of prototype instruments with pressurized metered dose inhaler (pMDI)-based formulations. Presented at Drug Delivery to the Lung XI, London, UK.
25. Leung, K., E. Louca, M. Grey, C.A. Tipples, and A.L. Coates. 2005. Use of the new generation pharmaceutical impactor for particle size distribution measurements of live biological aerosols. J. Aerosol Med. 18:414-426.
26. Newman, S.P., P.G.D. Pellow, M.M. Clay, and S.W. Clarke. 1985. Evaluation of jet nebulisers for use with gentamycin solution. Thorax 40:671-676.
27. Clay, M.M., D. Pavia, S.P. Newman, and S.W. Clarke. 1983. Factors influencing the size distribution of aerosols from jet nebulisers. Thorax 38:755-759.
28. Brown, J.S., K.L. Zeman, and W.D. Bennett. 2001. Regional deposition of coarse particles and ventilation distribution in healthy subjects and patients with cystic fibrosis. J. Aerosol Med. 14:443-454.
29. Coates, A.L., C.F. MacNeish, L.C. Lands, A. Smountas, D. Meisner, S. Kelemen, and E.B. Vadas. 1998. Factors influencing the rate of drug output during the course of wet nebulization. J. Aerosol Med. 11:101-111.
30. Byrne, N.M., P.M. Keavey, J.D. Perry, F.K. Gould, and D.A. Spencer. 2003. Comparision of lung deposition of colomycin using the HaloLite and Pari LC Plus nebulizers in patients with cystic fibrosis. Arch. Dis. Child 88:715-718.